Lai N, Lavosi V, Pinna S, Salis G, Colombo E, Vargiu P
Divisione di Chirurgia Generale, Ospedale Civile di Sassari.
G Chir. 1992 Jun-Jul;13(6-7):377-8.
The authors report data related to 212 surgical patients at risk because immunocompromised. Patients were divided in two homogeneous groups, one treated with Thymostimulin and the other as a control group, all affected by severe pathologies. Patients presenting postoperative complications directly related to technical reasons were excluded. Morbidity, postoperative hospitalization and mortality were the parameters considered. Positive results were obtained in the treated group compared to controls. Therefore, it is Authors' opinion that the treatment with Thymostimulin in immunocompromised patients is important in order to avoid or reduce postoperative infection rates.
作者报告了212名因免疫功能低下而面临手术风险的患者的数据。患者被分为两组，一组接受胸腺刺激素治疗，另一组作为对照组，两组患者均患有严重疾病。直接与技术原因相关的术后并发症患者被排除在外。所考虑的参数为发病率、术后住院时间和死亡率。与对照组相比，治疗组取得了阳性结果。因此，作者认为，在免疫功能低下的患者中使用胸腺刺激素进行治疗对于避免或降低术后感染率非常重要。
